Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces that it has selected ASC36, a once-monthly, potentially best-in-class subcutaneously administered amylin receptor agonist, as a clinical ...
Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced ...
Oppenheimer analyst Leland Gershell raised the firm’s price target on Xeris Biopharma (XERS) to $18 from $8 and keeps an Outperform rating on the ...
New findings published in Nature Medicine showed that people can enter prediabetes remission — and lower type 2 diabetes risk — even without weight loss. These findings could help motivate patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback